{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/a4c5de36-8260-4222-8e38-ff997dc73436/67362579f5bf73e251ec54c9?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Investment Trust Special, Burberry & Croda: The Companies and Markets Show ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b44742e856e989985776/1731601171383-d2f533ac-4397-44d6-b901-c85820058b94.jpeg?height=200","description":"<p>British-based luxury fashion brand<strong> Burberry (BRBY) </strong>has had a hard time of late. Our team delve into what’s gone wrong over and question whether the low valuation is attractive enough for investors to take a gamble.</p><p><br></p><p>It’s then onto our Investment Trust Special. We explore what trusts are most vulnerable to consolidation and some that could be fruitful in the changing macroeconomic environment.</p><p><br></p><p>Last up, it’s specialist British chemical company <strong>Croda (CRDA)</strong>. The latest update shows signs of life but two profit warnings over the past 18 months could hold back its growth. Julian Hofmann looks into the details.<strong>&nbsp;</strong></p><p><br></p><p><strong>Timestamps&nbsp;</strong></p><p>1:31 Burberry&nbsp;</p><p>15:38 Investment trusts</p><p>27:48 Croda&nbsp;</p><p><br></p><p>Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit <a href=\"http://www.investorschronicle.co.uk/podcasttrial\" rel=\"noopener noreferrer\" target=\"_blank\">www.investorschronicle.co.uk/podcasttrial</a>&nbsp;</p><p>*After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £1</p>","author_name":"Investors' Chronicle"}